MA29890B1 - Composition a base d'herbes pour les troubles inflammatoires - Google Patents

Composition a base d'herbes pour les troubles inflammatoires

Info

Publication number
MA29890B1
MA29890B1 MA30886A MA30886A MA29890B1 MA 29890 B1 MA29890 B1 MA 29890B1 MA 30886 A MA30886 A MA 30886A MA 30886 A MA30886 A MA 30886A MA 29890 B1 MA29890 B1 MA 29890B1
Authority
MA
Morocco
Prior art keywords
compound
compositions
relates
naphtho
octahydro
Prior art date
Application number
MA30886A
Other languages
English (en)
Inventor
Vijay Chauhan
Ashish Suthar
Dhananjay Sapre
Swati Bal-Tembe
Ashok Kumar Gangopadhyay
Asha Kulkarni-Almeida
Sapna Hasit Parikh
Original Assignee
Piramal Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Life Sciences Ltd filed Critical Piramal Life Sciences Ltd
Publication of MA29890B1 publication Critical patent/MA29890B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION MÉDICINALE COMPRENANT UN EXTRAIT DE FLEUR ET DE FRUIT DE LA PLANTE SPHAERANTHUS INDICUS. L'EXTRAIT DE SPHAERANTHUS INDICUS RENFERME UN COMPOSÉ, 3A-HYDROXY-5A,9-DIMÉTHYL-3- MÉTHYLENE-3A,4,5,5A,6,7,8,9B-OCTAHYDRO-3H-NAPHTHO[1,2-B]FURAN-2-ONE (7- HYDROXY-4,1 1 (13)-EUDESMADIEN-12,6-OLIDE) (COMPOSÉ 1 ) EN TANT QUE MARQUEUR BIOACTIF. L'INVENTION CONCERNE ÉGALEMENT UNE COMPOSITION COMPRENANT 3A-HYDROXY-5A,9-DIMÉTHYL- 3-MÉTHYLENE-3A,4,5,5A,6,7,8,9B-OCTAHYDRO-3H-NAPHTHO[1,2-B]FURAN-2-ONE (COMPOSÉ 1 ) COMME INGRÉDIENT ACTIF. DE PLUS, L'INVENTION ENGLOBE DES MÉTHODES DE FABRICATION DESDITES COMPOSITIONS ET DES MÉTHODES D'ADMINISTRATION À U N SUJET DEVANT ÊTRE TRAITÉ POUR DES TROUBLES INFLAMMATOIRES. L'INVENTION PORTE ÉGALEMENT SUR L'ACTIVITÉ INHIBITRICE DE CES COMPOSITIONS À L'ÉGARD DU FACTEUR $G(A) DE NÉCROSE DES TUMEURS (TNF- A) ET DE L'INTERLEUKINE (IL-1, IL-6, IL-8). ELLE CONCERNE EN OUTRE L'INHIBITION PAR LESDITS COMPOSITIONS DE L'EXPRESSION DE LA MOLÉCULE 1 D'ADHÉSION INTERCELLULAIRE (ICAM-1 ), DE LA MOLÉCULE 1 D'ADHÉSION DES CELLULES VASCULAIRES (VCAM-1 ) ET DE LA SÉLECTINE E. CES COMPOSTIONS PEUVENT ÉVENTUELLEMENT CONTENIR AU MOINS UN AGENT ANTI-INFLAMMATOIRE OU PEUVENT ÊTRE UTILISÉES EN ASSOCIATION AVEC AU MOINS UN AGENT ANTI-INFLAMMATOIRE.
MA30886A 2005-09-30 2008-04-29 Composition a base d'herbes pour les troubles inflammatoires MA29890B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1226MU2005 2005-09-30
US73644305P 2005-11-14 2005-11-14

Publications (1)

Publication Number Publication Date
MA29890B1 true MA29890B1 (fr) 2008-10-03

Family

ID=37900158

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30886A MA29890B1 (fr) 2005-09-30 2008-04-29 Composition a base d'herbes pour les troubles inflammatoires

Country Status (11)

Country Link
US (2) US7635494B2 (fr)
EP (1) EP1931366B1 (fr)
JP (1) JP5331962B2 (fr)
AU (1) AU2006296197B2 (fr)
CA (1) CA2624049C (fr)
EA (1) EA014070B1 (fr)
GE (1) GEP20115332B (fr)
HK (1) HK1112418A1 (fr)
MA (1) MA29890B1 (fr)
PL (1) PL1931366T3 (fr)
WO (1) WO2007036900A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200908958A (en) * 2007-07-27 2009-03-01 Piramal Life Sciences Ltd Tricyclic compounds for the treatment of inflammatory disorders
WO2009084032A2 (fr) * 2007-12-03 2009-07-09 Vedic Elements Private Limited Formulation topique hydrophobe stable à base de plantes
WO2012014216A1 (fr) * 2010-07-28 2012-02-02 Laila Nutraceuticals 7-hydroxyfrullanolide et ses analogues pour la prévention, la maîtrise et le traitement de troubles du métabolisme.
KR101682489B1 (ko) * 2009-02-02 2016-12-05 라일라 뉴트라슈티칼스 대사성 증후군의 조절을 위한 스파란터스 인디커스 및 가르시니아 망고스타나 유래의 조성물
US10105347B2 (en) 2009-02-02 2018-10-23 Laila Nutraceuticals Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
WO2011033524A2 (fr) * 2009-08-04 2011-03-24 Laila Nutraceuticals Agents dérivés de ficus hispida pour l'amélioration du syndrome métabolique et de maladies associées
WO2011083397A1 (fr) * 2010-01-05 2011-07-14 Himalaya Global Holdings Limited Composition phytothérapeutique pour les troubles de la peau
MY166221A (en) * 2010-09-11 2018-06-22 Laila Nutraceuticals Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
US8263579B2 (en) * 2011-01-24 2012-09-11 Piramal Healthcare Limited Anti-inflammatory compounds
AU2013336251A1 (en) * 2012-10-23 2015-06-04 Piramal Enterprises Limited Herbal composition for the prevention and treatment of TNF-alpha mediated diseases
AU2016281656B2 (en) * 2015-06-23 2019-05-30 Nobilis Therapeutics, Inc. Therapeutic immune modulation using noble gas compositions
MY190273A (en) * 2016-05-21 2022-04-11 Laila Impex Dietary supplements and compositions for enhancing physical performance and energy levels

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646687A (en) * 1994-12-29 1997-07-08 Lucent Technologies Inc. Temporally-pipelined predictive encoder/decoder circuit and method
US6204523B1 (en) * 1998-11-06 2001-03-20 Lumileds Lighting, U.S., Llc High stability optical encapsulation and packaging for light-emitting diodes in the green, blue, and near UV range
US6686676B2 (en) * 2001-04-30 2004-02-03 General Electric Company UV reflectors and UV-based light sources having reduced UV radiation leakage incorporating the same
US6989412B2 (en) * 2001-06-06 2006-01-24 Henkel Corporation Epoxy molding compounds containing phosphor and process for preparing such compositions
US6841647B2 (en) * 2001-11-06 2005-01-11 National Starch And Chemical Investment Holding Corporation Fluid resistant silicone encapsulant
US7160972B2 (en) * 2003-02-19 2007-01-09 Nusil Technology Llc Optically clear high temperature resistant silicone polymers of high refractive index
US7261441B2 (en) * 2004-02-27 2007-08-28 Avago Technologies Ecbu Ip (Singapore) Pte. Ltd. LED device and method for directing LED light
WO2006016228A2 (fr) * 2004-08-02 2006-02-16 Prashanth Kumar V Alkaloide peptide cytotoxique et compositions pharmaceutiques pour le traitement des maladies neoplastiques
US7229934B2 (en) * 2004-10-18 2007-06-12 International Business Machines Corporation Porous organosilicates with improved mechanical properties

Also Published As

Publication number Publication date
US20090269427A1 (en) 2009-10-29
EA200800850A1 (ru) 2008-10-30
HK1112418A1 (en) 2008-09-05
WO2007036900A3 (fr) 2007-08-02
CA2624049A1 (fr) 2007-04-05
US20080254157A1 (en) 2008-10-16
EP1931366B1 (fr) 2013-05-29
WO2007036900A2 (fr) 2007-04-05
JP2009510051A (ja) 2009-03-12
AU2006296197A1 (en) 2007-04-05
EA014070B1 (ru) 2010-08-30
AU2006296197A2 (en) 2008-06-05
AU2006296197B2 (en) 2012-08-09
EP1931366A2 (fr) 2008-06-18
US7635494B2 (en) 2009-12-22
JP5331962B2 (ja) 2013-10-30
US8206756B2 (en) 2012-06-26
CA2624049C (fr) 2016-01-12
PL1931366T3 (pl) 2013-11-29
GEP20115332B (en) 2011-11-25

Similar Documents

Publication Publication Date Title
MA29890B1 (fr) Composition a base d'herbes pour les troubles inflammatoires
MA30342B1 (fr) Nouvelles compositions pour des troubles capillaires et procede de preparation de celles-ci
BRPI0513464A (pt) composições fungicidas
ATE459357T1 (de) Kombinationen zur behandlung von multiplem myelom
TW200718418A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
FR2393531A1 (fr) Compositions fongicides pour l'agriculture a base de derives de 4-aminoquinazoline
BR0312232A (pt) Inibidores de caspases e seus usos
WO2005121778A3 (fr) Procedes d'identification, et composes utiles pour le traitement de maladies degeneratives et inflammatoires
MA27125A1 (fr) Composes de thienodibenzoazulene comme inhibiteurs de facteurs de tumeur de necrose
Bitasta et al. Aerva lanata: A blessing of mother nature
ES2426174T8 (es) Composición herbácea para trastornos inflamatorios
KR100371858B1 (en) Antimicrobial composition containing plant extract
Banisalam et al. Comparison between in vitro and in vivo antibacterial activity of Curcuma zedoaria from Malaysia
CO5280139A1 (es) Procedimiento para obtener plantas con un mayor contenido de flavonoides y compuestos fenolicos
WO2004087181A3 (fr) Combinaisons de principes actifs d'huiles contenant des acides gras $g(v)3 avec des extraits vegetaux contenant des polyphenols et utilisation desdites combinaisons
CA2439430A1 (fr) Extrait d'agastache rugosa et composition renfermant de la tilian ine isolee et purifiee a partir dudit extrait dote d'une activite anti-inflammatoire et activite anti-atherogene
Mantena et al. Anti inflammatory activity of Erythrina Variegata
Mohamed et al. Promising selective MAO-B inhibition by sesamin, a lignan from Zanthoxylum flavum stems
AR037334A1 (es) Composicion fungicida que comprende pirimetanil y al menos un derivado de acido fosforoso y utilizacion de esta composicion para la lucha contra las enfermedades de las plantas
Kulkarni Anti-inflammatory activity of Vitex trifolia Linn.(verbaneaceae) leaves extracts
AR025098A1 (es) Acumulacion de poliaminas en plantas
Kavyashree et al. A review on Tulasi (Ocimum sanctum Linn.)
Velayutham et al. A Concise Review on Phytochemical and Pharmacological Studies of Hybanthus enneaspermus (L.) F. Muell
Venkateswaran et al. Evaluation of Antihyperlipidemic Activity of Ethanolic Root Extract of Carica Papaya in Poloxamer—407 Induced Hyperlipidemia in Wistar Rats
Bhattacharya et al. In vitro regeneration of some lesser known medicinal Zingibers: a review